Go to page
 

Bibliographic Metadata

Title
Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine
AuthorJensen-Jarolim, Erika ; Singer, Jodef ; Fuerdoes, Irene ; Fazekas, Judit
Published in
Oncology Letters, Athens, 2016, Vol. 12, Issue 4, page 2271-2276
PublishedAthens : Spandidos Publications, 2016
LanguageEnglish
Document typeJournal Article
Keywords (EN)her-2 / dog / translational / cancer vaccine / oncology / mimotope / canine mammary-tumors / human-breast-cancer / drug development / pet dogs / adjuvant chemotherapy / gland tumors / trastuzumab / overexpression / her-2/neu / antibody
Project-/ReportnumberW 1205-B09
ISSN1792-1074
URNurn:nbn:at:at-ubmuw:3-1944 Persistent Identifier (URN)
DOI10.3892/ol.2016.5001 
Restriction-Information
 The work is publicly available
Files
Why man's best friend, the dog, could also benefit from an anti-HER-2 vaccine [0.47 mb]
Links
Reference
Classification
Abstract (English)

Human epidermal growth factor receptor-2 (HER-2) is a well-established target for anticancer anticancerprecision medicine in humans. A HER-2 homologue with 92% amino acid identity has been described in canine mammary tumors, which whichis termed here as dog epidermal growth factor receptor-2 (DER-2)', with similar biological implications as those in human breast cancer. Both antigens can principally be immunologically targeted by anti-HER-2 antibodies, such as trastuzumab; however, the in vivo application applicationof humanized antibodies to other species would lead to specific hypersensitivity reactions. Therefore, HER-2 mimotope vaccines that actively induce autologous trastuzumab-like immunoglobulins represent a novel and economic treatment option to overcome species-specific limitations. Thus, the present review proposes the implementation of clinical trials with HER-2 vaccines in canine cancer model modelpatients with spontaneous DER-2 positive mammary gland carcinomas in order to assess their safety and efficacy. This approach would not only pave the way into the veterinary oncology market, but would also similarly generate robust data for human trials and facilitate the testing of novel combinatorial treatments.

Stats
The PDF-Document has been downloaded 4 times.
License
CC-BY-NC-ND-License (4.0)Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License